Citations

Clear

127 citation(s) found for "Shari, G".

Validation of prototype biomarkers to identify risk factors of inflammatory adverse events (iAEs) following idecabtagene vicleucel (ide-cel) infusion in patients with relapsed and refractory multiple myeloma (RRMM) in KarMMa-3.
Sengupta, Sanhita , Amorosi, Clara J. , Takhar, Mandeep, Manier, Salomon , Juluri, Krishna R. , Kaeding, Allison, Piasecki, Julia , Campbell, Timothy , Kaiser, Shari M. , Shamsuzzaman, Md, Martin, Nathan , Lin, Yi , Baz, Rachid , Mashadi-Hossein, Afshin , Rytlewski, Julie

Mayo Clinic

Journal of Clinical Oncology | June 10, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 7529-7529

10.1200/jco.2024.42.16_suppl.7529 Get It

7529 Background: iAEs, such as cytokine release syndrome (CRS) and macrophage activation syndrome (MAS), can occur after infusion of chimeric antigen receptor T cell therapies such as ide-cel, but are typically low-grade and manageable with tocilizumab and corticosteroids. Although high-grade iAEs are rare with ide-cel, identification of patients at increased risk may improve management and remains an unmet need. Three composite biomarkers (multivariate models) of iAE risk were previously developed in a discovery cohort from the KarMMa and KarMMa-2 studies of ide-cel in RRMM (Mashadi-Hossein A, et al. J Clin Oncol 2023;41(16_suppl):e20005). Here, we validate these 3 prototype models for risk of developing high-grade iAEs after ide-cel infusion. Methods: Two models used pretreatment patient and routine clinical laboratory parameters; the third model also included change in 6 exploratory cytokines from baseline to 1 day following ide-cel infusion. To validate, each model was retrospectively applied to KarMMa-3 (NCT03651128) data in a blinded fashion, and sensitivity and specificity to identify grade ≥3 CRS and any-grade MAS were determined. Model performance thresholds used for sensitivity and specificity were 90% and 50%, respectively. Performance for identifying grade 2 CRS was also analyzed post hoc. Results: The first and simplest model comprised a manual algorithm with 7 features; it identified patients with grade ≥3 CRS or MAS with 85% sensitivity and 60% specificity. The second model comprised 19 routinely measured pretreatment features; it identified grade ≥3 CRS with 91% sensitivity and 59% specificity, and any-grade MAS with 60% sensitivity and 88% specificity. The third and most complex model comprised 7 pretreatment clinical features and 6 exploratory cytokines; it identified grade ≥3 CRS with 100% sensitivity and 51% specificity, and any-grade MAS with 100% sensitivity and 81% specificity. None of the models identified grade ≥2 CRS with passable sensitivity or specificity. Clustering analyses across all features showed that only a subset of grade 2 CRS cases was within the previously identified high-risk iAE cluster while the remaining grade 2 CRS cases were spread across other clusters. Conclusions: Two of the 3 composite biomarkers met validation criteria for grade ≥3 CRS risk. Criteria were not met for grade 2 CRS, suggesting these models are specific to higher-grade events and that grade 2 CRS represents a more heterogeneous group of patients. While high-grade iAEs are rare with ide-cel, these models may further optimize the robust benefit–risk profile that ide-cel has demonstrated by helping identify, prior to or shortly after infusion, patients most at risk for severe events. Clinical trial information: NCT03651128 .
Fertility among young breast cancer survivors attempting pregnancy: A prospective, multicentre cohort study.
Niman, Samuel M. , Dibble, Kate E. , Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Gelber, Shari , Peppercorn, Jeffrey , Schapira, Lidia , Come, Steven E. , Ginsburg, Elizabeth S. , Sorouri, Kimia , Zheng, Yue , Kirkner, Gregory J. , Tamimi, Rulla M. , Borges, Virginia F. , Warner, Ellen , Lambertini, Matteo , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 1518-1518

10.1200/jco.2024.42.16_suppl.1518 Get It

1518 Background: Despite high interest among young women diagnosed with breast cancer (BC) in future fertility, prior research has been hampered by short follow-up and lack of prospective assessment of pregnancy attempts. We sought to describe fertility outcomes among young women participating in a prospective cohort who reported pregnancy attempt post-BC diagnosis. Methods: Women with stage 0-III BC in the Young Women's Breast Cancer Study (YWS, NCT01468246), a multicenter, prospective cohort of women diagnosed at age ≤40 from 2006-2016 who reported attempting pregnancy post-diagnosis were included. Those with prior hysterectomy, bilateral oophorectomy, or metastatic disease at diagnosis were excluded. Data on attempting pregnancy and fertility outcomes were obtained from serial surveys. Multivariable logistic regression with stepwise model selection was used to identify factors associated with pregnancy and live birth. Results: Among 1213 eligible participants, 197 reported any attempt of pregnancy (16%) over a median follow-up of 11 years (range: 3-17). Among attempters, median age at diagnosis was 32 years (range: 17-40); 74% were non-Hispanic White; 41% had stage I, 35% stage II, 10% stage III, and 14% stage 0 BC; 76% had HR+ disease; 68% received chemotherapy; 57% received endocrine therapy within one year post-diagnosis; 13% were BRCA1/2 pathogenic variant (PV) carriers; 51% reported financial comfort at baseline; 51% were nulligravida and 72% nulliparous at diagnosis; 28% had undergone fertility preservation consisting of egg/embryo freezing at diagnosis; 15% reported a history of infertility before BC diagnosis. Most (73%) reported ≥1 pregnancy after diagnosis and 65% reported ≥1 live birth. Median time from diagnosis to first pregnancy was 48 months (range: 6-125). In the multivariable model, greater age at diagnosis (odds ratio [OR] 0.82 per year increase, 95% CI 0.74-0.90, P<0.0001) was negatively associated with pregnancy, while financial comfort at baseline (OR 2.04, 95% CI 1.01-4.12, P=0.047) was predictive of pregnancy. For live births, greater age at diagnosis was negatively associated (OR 0.82 per year increase, CI 95% 0.76-0.90, P<0.0001) while having undergone fertility preservation at diagnosis was predictive (OR 2.78, 95% CI 1.29-6.00, P=0.009). History of infertility, nulliparity at diagnosis, tumor characteristics, cancer treatment, race, ethnicity, and BRCA1/2 PV status were not associated with either outcome. Conclusions: This is the first prospective study with greater than 10 years of follow-up to report fertility outcomes in young BC survivors accounting for attempting pregnancy. The majority achieved a pregnancy and most reported a live birth. Our findings can be incorporated into the counseling of young BC patients and survivors, and highlight the need for accessibility of fertility preservation services for this population. Clinical trial information: NCT01468246 .
Health equity engineering: Optimizing hope for a new generation of healthcare
Enders, Felicity , Brooks, Tayla R., Carr, Allison R. , Cullen, John P. , DiazGranados, Deborah , Gaba, Ayorkor , Johnson, Leigh , Messinger, Shari , Milam, Adam J. , Perkins, Susan M. , Pineda, Tiffany Danielle , Periyakoil, Vyjeyanthi S. , Hanlon, Alexandra L. , Enders, Felicity T , Golembiewski, Elizabeth H , Cullen, John P , DiazGranados, Deborah , Gaba, Ayorkor , Orellana, Minerva A , Pineda, Tiffany D Chisholm , Milam, Adam J , Messinger, Shari , Golembiewski, Elizabeth H. , Balls‐Berry, Joyce E. , Brooks, Tayla Rashanaye , Menser, Terri , Orellana, Minerva , Thurston, Sally W.

Mayo Clinic

Journal of Clinical and Translational Science | May 22, 2024 | Volume: 8 | Issue: 1 | Pages: No page available

10.1017/cts.2024.549 | PMID 39478773 Get It

Abstract Medical researchers are increasingly prioritizing the inclusion of underserved communities in clinical studies. However, mere inclusion is not enough. People from underserved communities frequently experience chronic stress that may lead to accelerated biological aging and early morbidity and mortality. It is our hope and intent that the medical community come together to engineer improved health outcomes for vulnerable populations. Here, we introduce Health Equity Engineering (HEE), a comprehensive scientific framework to guide research on the development of tools to identify individuals at risk of poor health outcomes due to chronic stress, the integration of these tools within existing healthcare system infrastructures, and a robust assessment of their effectiveness and sustainability. HEE is anchored in the premise that strategic intervention at the individual level, tailored to the needs of the most at-risk people, can pave the way for achieving equitable health standards at a broader population level. HEE provides a scientific framework guiding health equity research to equip the medical community with a robust set of tools to enhance health equity for current and future generations.
The Clinical Utility of a Chemokine-Cytokine Multiplex Assay in Fibromyalgia Diagnosis at an Academic Medical Center
Mohabbat, Arya B. , Wight, Elizabeth C. , Johnson, Tammi R., McCarthy, Page E., Aakre, Christopher A. , Bornstein, Shari L. , Salonen, Bradley R. , Bierle, Dennis M. , Johnson, Tammi R., Ganesh, Ravindra

Mayo Clinic

No container title available | May 13, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4145257/v1 Get It

Abstract Introduction/Objective: To assess the clinical utility of the FM/a® chemokine-cytokine assay in diagnosing fibromyalgia at an academic medical center. Methods: We performed a cross-sectional study on 50 patients diagnosed with fibromyalgia at a specialty fibromyalgia clinic between January 1, 2021 through July 31, 2021. Patients completed questionnaires and provided a venous blood sample sent to EpicGenetics, to complete the FM/a® test. Demographic, symptom, and historical data was obtained from chart review. Statistical analysis was performed. Results: Of 50 patients with a clinical diagnosis of fibromyalgia, the FM/a® test was positive in 45 (90%). Performance of the FM/a® test compared to the 2016 ACR criteria yielded an odds ratio of 3.5 with sensitivity of 0.91, specificity of 0.25. Univariate regression demonstrated an area under the curve (AUC) of 0.7337, which improved to 0.89 when adjusted for age, gender, and race. When compared to the 1990 ACR criteria, a positive FM/a® test had an odds ratio of 2.33 with sensitivity 0.92 and specificity 0.17. Univariate regression analysis demonstrated an AUC of 0.571, when adjusted for age, gender and race, AUC was similar at 0.585. Conclusion: The FM/a® test performed well overall, though inferiorly compared to the 1990 and 2016 ACR diagnostic criteria. When adjusted for age, gender, and race the test performed almost equivalently to the 2016 ACR criteria. The FM/a® test may be useful in general clinical practices to differentiate patients who are more likely to have FM.
Bovine Collagen Xenografts as Cost-Effective Adjuncts for Granulating Surgical Defects
Ladd, Ryan, Demer, Addison M. , Ochoa, Shari A. , Arpey, Christopher J., Demer, Addison, Ochoa, Shari, Arpey, Christopher

Mayo Clinic

Dermatologic Surgery | May 9, 2024 | Volume: 50 | Issue: 9 | Pages: 884-886

10.1097/dss.0000000000004216 | PMID 38722746 Get It

Pragmatic strategies to address health disparities along the continuum of care in chronic liver disease
Brahmania, Mayur , Rogal, Shari S. , Serper, Marina , Goldberg, David S. , Mathur, Amit K. , Wilder, Julius , Vittorio, Jennifer , Yeoman, Andrew D. , Lazo, Mariana , Kardashian, Ani , Verma, Manisha , Verna, Elizabeth C. , Simpson, Dinee C. , Rosenblatt, Russell , McElroy, Lisa M. , Wadwhani, Sharad I., Strauss, Alexandra T. , Aiza, Ignacio , Carr, Rotonya M. , Yang, Jin Mo , Brady, Carla W. , Fortune, Brett E. , Rogal, Shari , Patel, Arpan , Goldberg, David , Mathur, Amit , Wilder, Julius , Vittorio, Jennifer M , Yeoman, Andrew , Lazo, Mariana , Kardashian, Ani , Asrani, Sumeet K , Spann, Ashley , Ufere, Nneka N , Verma, Manisha , Verna, Elizabeth C , Simpson, Dinee , Schold, Jesse D , Rosenblatt, Russell , McElroy, Lisa M , Wadhwani, Sharad I , Lee, Tzu-Hao , Strauss, Alexandra T , Aiza, Ignacio , Carr, Rotonya M , Yang, Jin Mo , Brady, Carla , Serper, Marina , Patel, Arpan , Rich, Nicole E. , Asrani, Sumeet K. , Spann, Ashley , Lee, Tzu‐Hao , Chung, Raymond T.

Mayo Clinic

Hepatology Communications | May 2, 2024 | Volume: 8 | Issue: 5 | Pages: No page available

10.1097/hc9.0000000000000413 | PMID 38696374 Get It

Racial, ethnic, and socioeconomic disparities exist in the prevalence and natural history of chronic liver disease, access to care, and clinical outcomes. Solutions to improve health equity range widely, from digital health tools to policy changes. The current review outlines the disparities along the chronic liver disease health care continuum from screening and diagnosis to the management of cirrhosis and considerations of pre-liver and post-liver transplantation. Using a health equity research and implementation science framework, we offer pragmatic strategies to address barriers to implementing high-quality equitable care for patients with chronic liver disease.
Abstract PO2-12-01: Five-year quality of life (QOL) trajectories among young breast cancer (BC) survivors
Sella, Tal , Zheng, Yue , Ruddy, Kathryn J. , Gelber, Shari , Peppercorn, Jeffrey , Schapira, Lidia , Come, Steven E. , Rosenberg, Shoshana M. , Tamimi, Rulla M. , Borges, Virginia F. , Winer, Eric P. , Partridge, Ann H.

Mayo Clinic

Cancer Research | May 2, 2024 | Volume: 84 | Issue: 9_Supplement | Pages: PO2-12-01-PO2-12-01

10.1158/1538-7445.sabcs23-po2-12-01 Get It

Abstract Background: Young BC survivors are at risk for impaired QOL in part due to issues that are unique to their life stage. We sought to characterize trajectories of QOL in the 5 years following diagnosis among young BC survivors as well as evaluate patient and clinical characteristics associated with poorer or deteriorating QOL trajectories over time. Methods: Women diagnosed with stage I-III BC at age ≤40 enrolled in the Young Women’s BC Study, a prospective cohort in North America, who completed ≥2 study surveys through 5 years of post-diagnosis follow-up. QOL was evaluated with the Cancer Rehabilitation Evaluation System (CARES) physical, psychosocial, and sexual subscale scores. Demographic, treatment, and clinical characteristics were ascertained through surveys and chart review. Longitudinal trajectories for each CARES subscale were defined using group-based trajectory modeling; associations between patient/clinical characteristics and trajectory group membership were estimated for each subscale using multivariable multinomial logistic regression. Results: Among 900 women, median age at diagnosis was 36 (range: 17-40) 89% were white, 2% Black, and 4% Hispanic. At baseline, 73% were partnered, 61% parous and 49% perceived themselves as financially comfortable. Most had hormone-receptor positive (74%), HER2-negative (70%) BC, and most received chemotherapy (82%); 36% underwent mastectomy with radiation. Physical and psychosocial scores each clustered into 4 trajectories, with &gt;75% of participants clustering in groups reflecting excellent or good QOL that was stable over time and few (6% for physical and 4% for psychosocial) clustering into groups that reflected poorer QOL at baseline that did not improve over time. Sexual health trajectories were more variable, clustering into 5 trajectories, with over half of participants clustered into groups reflecting good (35%) or excellent (20%) QOL that remained relatively stable over time, 22% clustered into a trajectory that was poor at baseline but moderately improved over follow-up, 13% in a group that reflected deteriorating from moderate-to-poor QOL and 11% in a group with poor QOL at baseline that did not improve over time. In multivariable regression analyses (Table), factors associated with clustering in a poorer trajectory (vs. clustering in an excellent trajectory), in multiple QOL domains included baseline financial discomfort (associated with poorer QOL across all 3 domains), mastectomy+radiation (vs. lumpectomy, associated with poorer QOL across all 3 domains); chemotherapy receipt (associated with poorer physical and sexual health trajectories); and baseline BMI &gt;25 (vs. 18.5-24.9, associated with poorer physical and poorer/deteriorating sexual health trajectories). Conclusions: Young BC survivors follow distinct QOL trajectories in survivorship. While most will not experience substantial QOL impairment through the first 5 years following diagnosis, a substantial minority report persistently poor or deteriorating QOL. The association between more extensive local therapy and poorer physical/psychosocial/sexual health trajectories underscores the importance of communicating the potential for negative QOL outcomes when women are making surgical decisions. Additionally, the pervasive impact of financial wellbeing on multiple QOL domains supports the potential value of systematic screening for and addressing of financial distress to prevent or mitigate financial toxicity in survivorship Factors associated with clustering in poorer/deteriorating (vs. excellent) QOL trajectories *Reference trajectory=excellent QOL Citation Format: Tal Sella, Zheng Yue, Kathryn Ruddy, Shari Gelber, Rulla Tamimi, Jeffrey Peppercorn, Lidia Schapira, Virginia Borges, Steven Come, Eric Winer, Ann Partridge, Shoshana Rosenberg. Five-year quality of life (QOL) trajectories among young breast cancer (BC) survivors [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO2-12-01.
Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Abu‐Rustum, Nadeem R. , Yashar, Catheryn M. , Barber, Emma L. , Bradley, Kristin , Brooks, Rebecca , Campos, Susana M. , Chino, Junzo , Chon, Hye Sook, Damast, Shari , Fisher, Christine M. , Frederick, Peter J., Gaffney, David K. , Gaillard, Stéphanie , Giuntoli, Robert , Glaser, Scott , Howitt, Brooke E. , Kendra, Kari , Mantia-Smaldone, Gina , Mariani, Andrea , Nagel, Christa , Nekhlyudov, Larissa , Podoll, Mirna, Rodabaugh, Kerry J. , Salani, Ritu , Schorge, John O., Siedel, Jean , Sisodia, Rachel , Soliman, Pamela T. , Ueda, Stefanie , Urban, Renata R. , Wyse, Emily , Zanotti, Kristine , McMillian, Nicole R., Espinosa, Sara, Gaillard, Stéphanie , Arend, Rebecca C. , Crispens, Marta Ann , Holmes, Jordan A. , Lea, Jayanthi Sivasothy , Lee, Nita Karnik , Mutch, David G. , Wethington, Stephanie L.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 18, 2024 | Volume: 22 | Issue: 2 | Pages: 117-135

10.6004/jnccn.2024.0013 | PMID 38503056 Get It

Vulvar cancer is annually diagnosed in an estimated 6,470 individuals and the vast majority are histologically squamous cell carcinomas. Vulvar cancer accounts for 5% to 8% of gynecologic malignancies. Known risk factors for vulvar cancer include increasing age, infection with human papillomavirus, cigarette smoking, inflammatory conditions affecting the vulva, and immunodeficiency. Most vulvar neoplasias are diagnosed at early stages. Rarer histologies exist and include melanoma, extramammary Paget’s disease, Bartholin gland adenocarcinoma, verrucous carcinoma, basal cell carcinoma, and sarcoma. This manuscript discusses recommendations outlined in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for treatments, surveillance, systemic therapy options, and gynecologic survivorship.
NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024
Abu‐Rustum, Nadeem R. , Yashar, Catheryn M. , Arend, Rebecca C. , Barber, Emma L. , Bradley, Kristin , Brooks, Rebecca , Campos, Susana M. , Chino, Junzo , Chon, Hye Sook, Damast, Shari , Fisher, Christine M. , Frederick, Peter J., Gaffney, David K. , Gaillard, Stéphanie , Giuntoli, Robert , Glaser, Scott , Holmes, Jordan A. , Howitt, Brooke E. , Mantia-Smaldone, Gina , Mariani, Andrea , Nagel, Christa , Nekhlyudov, Larissa , Podoll, Mirna, Rodabaugh, Kerry J. , Salani, Ritu , Schorge, John O., Siedel, Jean , Sisodia, Rachel , Soliman, Pamela T. , Ueda, Stefanie , Urban, Renata R. , Wyse, Emily , McMillian, Nicole R., Aggarwal, Shaili, Espinosa, Sara, Gaillard, Stéphanie , Crispens, Marta Ann , Lea, Jayanthi Sivasothy , Mutch, David G.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 11, 2023 | Volume: 21 | Issue: 12 | Pages: 1224-1233

10.6004/jnccn.2023.0062 | PMID 38081139 Get It

The NCCN Guidelines for Cervical Cancer provide recommendations for all aspects of management for cervical cancer, including the diagnostic workup, staging, pathology, and treatment. The guidelines also include details on histopathologic classification of cervical cancer regarding diagnostic features, molecular profiles, and clinical outcomes. The treatment landscape of advanced cervical cancer is evolving constantly. These NCCN Guidelines Insights provide a summary of recent updates regarding the systemic therapy recommendations for recurrent or metastatic disease.
Conception and pregnancy among women with a live birth after breast cancer treatment: A survey study of young breast cancer survivors
Sorouri, Kimia , Sella, Tal , Rosenberg, Shoshana M. , Loucks, Maggie, Kirkner, Gregory J. , Snow, Craig , Ruddy, Kathryn J. , Gelber, Shari , Peppercorn, Jeffrey , Schapira, Lidia , Come, Steven E. , Kirkner, Gregory , Schapira, Lidia , Warner, Ellen , Partridge, Ann H , Snow, Craig , Tamimi, Rulla M. , Borges, Virginia F. , Warner, Ellen , Partridge, Ann H.

Mayo Clinic

Cancer | October 26, 2023 | Volume: 130 | Issue: 4 | Pages: 517-529

10.1002/cncr.35066 | PMID 37880931 Get It

AbstractBackgroundBreast cancer (BC) is the most common malignancy in women of reproductive age. This study sought to explore the postcancer conception and pregnancy experience of young BC survivors to inform counseling.MethodsIn the Young Women's Breast Cancer Study (NCT01468246), a multicenter, prospective cohort, participants diagnosed at age ≤40 years with stage 0‐III BC who reported ≥1 postdiagnosis live birth were sent an investigator‐developed survey.ResultsOf 119 eligible women, 94 (79%) completed the survey. Median age at diagnosis was 32 years (range, 17–40) and at first postdiagnosis delivery was 38 years (range, 29–47). Most had stage I or II (77%) and HR+ (78%) BC; 51% were nulligravida at diagnosis. After BC treatment, most (62%) conceived naturally, though 38% used assisted reproductive technology, 74% of whom first attempted natural conception for a median of 9 months (range, 2–48). Among women with a known inherited pathogenic variant (n = 20), two underwent preimplantation genetic testing. Of 59 women on endocrine therapy before pregnancy, 26% did not resume treatment. Hypertensive disorders of pregnancy (20%) was the most common obstetrical condition. Nine percent of newborns required neonatal intensive care unit admission and 9% had low birth weight.ConclusionAmong women with live births after BC treatment, most conceived naturally and having a history of BC did not appear to negatively impact pregnancy complications, though the high rate of hypertensive disorders of pregnancy warrants further investigation. The prolonged period of attempting natural conception for some survivors suggests the potential need for improved understanding and counseling surrounding family planning goals after BC.